Pramiracetam
Cas No.: 68497-62-1
What is pramiracetam?
Pramiracetam (pramiracetamum) is a derivative of piracetam, a preparation famous for its nootropic properties. Other terms for this compound are diisoprop-yl-(2-oxopyrrolidin-1-yl)acetamide and CI-879, its trade name is Pramistar (Menarini concern).
The compound was synthesized as a more effective alternative to piracetam. Its primary profile of action is to support cognitive functions such as memory, concentration, and information processing.
The use of pramiracetam
Pramiracetam is described as an extremely effective “brain doping”. This is supported by promising results from clinical trials. This is because it turns out that even a single intake of the product improves the results of cognitive tests. The use of pramiracetam prior to scheduled memory tests yielded better results than in the group without such supplementation. Pramiracetam supplementation has also proven effective in young people who have experienced head trauma and hypoxic brain injury. This means that the product comprehensively supports the work of the central nervous system.
Mechanism of action
Pramiracetam affects numerous neurotransmitter systems, such as the serotonin, GABAergic, dopaminergic and adrenergic systems. Most characteristic of this preparation is its effect on widening the “bottleneck” in the synthesis of acetylcholine. This translates into the formulation’s effect on choline reuptake and the abolition of choline’s inhibitory effect on acetylcholine synthesis. Other racetams, such as coluracetam, also exhibit this mechanism of action.
Pramiracetam – dosage
The recommended dosage is 1200 mg per day. This amount can be taken in two doses of 600 mg or three doses of 400 mg. The product works mainly on an ad hoc basis, so in order to improve mental work and learning, a dosage regimen of 2×600 mg per day is more recommended.
References:
- De Vreese LP et al. “Memory training and drug therapy act differently on memory and metamemory functioning: evidence from a pilot study.” Arch Gerontol Geriatr. 1996;22 Suppl 1:9-22; https://www.sciencedirect.com/science/article/abs/pii/0167494396869068
- Claus JJ et al. “Nootropic drugs in Alzheimer’s disease: symptomatic treatment with pramiracetam.” Neurology. 1991 Apr;41(4):570-4; https://pubmed.ncbi.nlm.nih.gov/2011259/
- McLean A Jr, Cardenas DD, Burgess D, Gamzu E. Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia. Brain Inj. 1991 Oct-Dec;5(4):375-80; https://pubmed.ncbi.nlm.nih.gov/1786500/
